Mettmann, Nordrhein-Westfalen, Germany The main office of represented VC is situated in the Mettmann. The company was established in Europe in Germany.
The high activity for fund was in 2001. The fund is constantly included in less than 2 deals per year. The top amount of exits for fund were in 2012. Deals in the range of 10 - 50 millions dollars are the general things for fund.
Moreover, a startup needs to be at the age of 6-10 years to get the investment from the fund. Among the most popular fund investment industries, there are Marketplace, Biotechnology. Among the most popular portfolio startups of the fund, we may highlight Cardion, EpiCept Corporation, EpiCept Corporation. For fund there is no match between the country of its foundation and the country of its the most frequent investments - United States.
The standard case for the fund is to invest in rounds with 6 partakers. Despite the Gold-Zack AG, startups are often financed by Techno Venture Management, AlpInvest Partners, KBL Healthcare Ventures. The meaningful sponsors for the fund in investment in the same round are Techno Venture Management, Vontobel, KBL European Private Bankers. In the next rounds fund is usually obtained by Thuja Capital, Vontobel, Techno Venture Management.
Related Funds
Funds with similar focus
| Fund Name | Location |
| Alpha Startups | Beijing, Beijing, China |
| Evolution Financial Group | New York, New York, United States |
| InOvate Communications Group | California, San Ramon, United States |
| Qurate Retail | Colorado, Englewood, United States |
| Reefknot Investments | Central, Central Region, Singapore |
| Shunde Foundation For Innovation and Entrepreneurship | China, Foshan, Guangdong Province |
| Wynnchurch Capital | Illinois, Rosamond, United States |
| Xindali Capital | China, Guangdong, Shenzhen |
| zVentures | California, San Francisco, United States |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
EpiCept Corporation | $13M | 10 Jan 2001 | New Jersey, United States |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
EpiCept Corporation | $13M | 10 Jan 2001 | New Jersey, United States |
